Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 4/20 | 0.49 |
| ▸ | GRM5 | P41594 | 5/20 | 0.42 |
| ▸ | KCNJ5 | P48544 | 2/20 | 0.37 |
| ▸ | KCNJ3 | P48549 | 2/20 | 0.37 |
| ▸ | MMP13 | P45452 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.33 |
| ▸ | TOP1 | P11387 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22590518 | 0.78 | RIPK1 (0.47) | RIPK1GRM5MMP13 | |
| SCHEMBL23900235 | 0.76 | RIPK1 (0.46) | RIPK1GRM5PIK3CDPIK3R1 | |
| SCHEMBL23900349 | 0.75 | RIPK1 (0.48) | RIPK1GRM5 | |
| SCHEMBL23900311 | 0.73 | GRM5 (0.51) | RIPK1GRM5 | |
| SCHEMBL22590552 | 0.70 | LMNA (0.47) | RIPK1 | |
| SCHEMBL13778489 | 0.67 | KCNJ5 (0.47) | GRM5KCNJ5KCNJ3MMP13EGFR | |
| SCHEMBL30832137 | 0.66 | RIPK1 (0.41) | RIPK1GRM5KCNJ5KCNJ3MMP13 | |
| SCHEMBL3728394 | 0.64 | GRM5 (0.46) | GRM5KCNJ5KCNJ3MMP13EGFR | |
| SCHEMBL30250586 | 0.62 | RIPK1 (0.54) | RIPK1 | |
| SCHEMBL21500799 | 0.62 | RIPK1 (0.39) | RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11584758-B2 | RIP1K inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-20210317135-A1 | RIP1K INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2021-10-14 | — | — | US | disclosed |
| WO-2021203011-A1 | RIP1K INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2021-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584758-B2 | RIP1K inhibitors | RIPK1, RIPK2, RIPK3 | RIPK1 1/4885GRM5 2384/4885KCNJ5 3054/4885 |
| US-20210317135-A1 | RIP1K INHIBITORS | RIPK1, RIPK2, RIPK3 | RIPK1 1/4885GRM5 2384/4885KCNJ5 3054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.